Entrada Therapeutics, Inc. (TRDA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$5.06+7.20%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · TRDA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 92.5% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -60.0% |
Growth built into the price is above our model estimate.
The price assumes 152.5 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
TRDA — litigation filed
Dated 2026-10-14
Other Events. Update on ENTR-601-45 On October 14, 2026, the Company announced positive topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of the Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45 in ambulatory participants with a confirmed mutation in the DMD gene amenable to exon 45 skipping. ELEVATE-45-201 is a global, two-part, randomized, double-blind, placebo-controlled Phase 1/2 study evaluating the safety, tolerability and eff…
Why it matters: The 12 mg/kg results can test whether a higher dose adds to the early function gains seen at 6 mg/kg.
Watch forQ1 2027 data show a rise in dystrophin or better function at 12 mg/kg, with no serious safety issue.
Also watch forQ1 2027 data show no rise in dystrophin or better function, a serious safety issue, or a delay beyond Q1.
Why it matters: The study can show whether the partnered DM1 drug changes splicing or muscle function. The result tests progress in this partnership.
Watch forVertex reports H2 2026 results. Look for a rise in the splicing index or better muscle function, with no serious safety issue.
Also watch forResults show no rise in the splicing index or better muscle function. They show a serious safety issue or a delay past H2 2026.
Why it matters: Cash fell to $223.0 million by June 2026. A shorter runway could put pressure on the clinical plans.
Worry ifA later company update says cash can fund operations into Q3 2027 or later.
Less concerning ifA later update moves the cash runway end date before Q3 2027.
Why it matters: The 10 mg/kg results will test whether a higher dose raises dystrophin beyond the 0.10% mean gain at 5 mg/kg.
Watch forH1 2027 results show a mean dystrophin gain above 0.10% at 10 mg/kg, with no new serious safety issue.
Also watch forThe mean gain is 0.10% or less, a serious safety issue appears, or results slip past H1 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$318 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $736 loss on $10,000 · 7.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,274 loss on $10,000 · 72.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.